Netherlands Confirms Intent to Ban Ashwagandha -What Supplement Brands Must Do Now
The Dutch Ministry of Health confirmed its intent to ban ashwagandha on 10 April 2026, with no effective date yet set. Denmark already bans leaf-derived ashwagandha and France has an ANSES advisory. Supplement brands with Netherlands-based EU fulfillment should assess affected products and a realistic effective date now.
EU Health Supplement Market Entry for US Brands : The 2026 Compliance Guide
The European health supplement market exceeds EUR 10 billion in 2026, but EU rules differ sharply from the US. Before placing a product on the EU market, US brands must clear Novel Food status, map health claims to the EU permitted list, check member state ingredient restrictions, and meet FIC labeling and PPWR packaging requirements.
EU Sports Nutrition Market Entry: What US Brands Need to Comply With Before Shipping the First Unit
The EU sports nutrition market is worth $6.61 billion in 2026. Before a single unit ships, US brands must answer five compliance questions in order: Novel Food status, EU permitted health claims, member state ingredient restrictions, FIC-compliant labeling and PPWR packaging. The sequence matters, and each question has a definite answer rather than guesswork.
EFSA’s Positive Safety Opinion on NMN Opens the EU Authorization Path
EFSA published a positive safety opinion on beta-NMN on May 13, 2026, confirming 300mg per day safe for the general adult population and formally opening the EU Novel Food authorization pathway. For US sports nutrition brands, this is the signal that EU market access for NMN is now a near-term target, not a regulatory unknown. EU authorization typically follows a positive EFSA opinion within five to seven months, putting the practical entry window at Q4 2026 to Q1 2027.